Efficacy and immune function of Lianhua qingfei granules combined with paramivir on viral acute upper respiratory tract infection in children

doi:10.3877/cma.j.issn.1673-5250.2023.03.016

Objective

To explore therapeutic effects and immune function of lianhua qingwen granules combined with peramivir on viral acute upper respiratory tract infection (ARI) in children.

Methods

A total of 126 children with viral ARI admitted in Department of Pediatrics of the Second People′s Hospital of Hefei City from January 2019 to January 2022 were selected in this study. By simple random sampling method, they were divided into research group (n=42), control group(n=42) and blank control group(n=42), respectively. Regime of research group was treated by peramivir combined with lianhua qingwen granules, control group was treated with peramivir, and blank control group was treated with conventional symptomatic treatment. Clinical symptom remission time, clinical efficacy, levels of serum CD4⁺, CD8⁺ values and CD4⁺ /CD8⁺, levels of serum immunoglobulin(Ig)M, IgG and IgA, and incidence of treatment-related adverse reactions were statistically analyzed among 3 groups before and on the 5th day atter treatment by different regimes. The procedure followed in this study is in line with the Helsinki Declaration of the World Medical Association as amended in 2013. Written informed consent was obtained from all research participants. There were no statistically significant differences in clinical data such as gender and age composition ratio, course and severity of viral ARI of children among 3 groups(P>0.05).

Results

①The time for body temperature to drop, the time for body temperature to return to normal, the time for sore throat to disappear, and the time for pulmonary rales to disappear in research group were all significantly shorter than those in control group and blank control group, and the differences were statistically significant (P<0.05). ②On the 5th day of treatment, compared within the group, the serum CD4⁺ level and CD4⁺ /CD8⁺ value, as well as the serum IgM, IgG and IgA levels in 3 groups were significantly higher than those before the treatment, but the serum CD8⁺ level was significantly lower than that before the treatment, and all the differences were statistically significant (P<0.05). ③ On the 5th day of treatment, among serum CD4⁺ level and CD4⁺ /CD8⁺ value, as well as serum IgM, IgG and IgA levels in research group were significant higher than those in control group and blank control group, while serum CD8⁺ level was significantly lower than those in control group and blank control group, and the above differences were also statistically significant (P<0.05). ④The incidences of treatment-related adverse reactions in 3 groups were all low, and there was no statistically significant difference among 3 groups (P>0.05).

Conclusions

The combination of lianhua qingwen granule combined with peramivir in treatment of viral ARI in children is helpful to improve clinical efficacy, significantly improve symptoms such as fever, and effectively improve their immune function, and have good safety.

Key words: Respiratory tract infections, Medicine, Chinese traditional, Immune indices, Lianhua qingwen capsule, Palamivir, Antiviral drug, Child

表1 3组病毒性ARI患儿临床症状缓解时间比较(±s)

组别	例数	体温开始下降时间(h)	体温恢复至正常所需时间(h)	咽喉肿痛消失时间(d)	肺啰音消失时间(d)
研究组	42	12.2±1.1	21.1±3.4	2.4±0.5	3.0±0.1
对照组	42	18.0±2.1	25.3±3.2	3.3±0.5	4.1±1.1
空白对照组	42	20.1±2.3	27.0±2.2	4.1±0.3	4.5±1.0
总体比较(F值/P值)		193.37/<0.001	43.62/<0.001	154.48/<0.001	23.54/<0.001
两两比较(q值/P值)
研究组vs对照组		19.71/<0.001	9.13/<0.001	13.15/<0.001	8.29/<0.001
研究组vs空白对照组		26.85/<0.001	12.83/<0.001	24.84/<0.001	11.30/<0.001
对照组vs空白对照组		7.14/<0.001	3.70/<0.001	11.69/0.035	3.01/0.035

表1 3组病毒性ARI患儿临床症状缓解时间比较(±s)

组别	例数	体温开始下降时间(h)	体温恢复至正常所需时间(h)	咽喉肿痛消失时间(d)	肺啰音消失时间(d)
研究组	42	12.2±1.1	21.1±3.4	2.4±0.5	3.0±0.1
对照组	42	18.0±2.1	25.3±3.2	3.3±0.5	4.1±1.1
空白对照组	42	20.1±2.3	27.0±2.2	4.1±0.3	4.5±1.0
总体比较(F值/P值)		193.37/<0.001	43.62/<0.001	154.48/<0.001	23.54/<0.001
两两比较(q值/P值)
研究组vs对照组		19.71/<0.001	9.13/<0.001	13.15/<0.001	8.29/<0.001
研究组vs空白对照组		26.85/<0.001	12.83/<0.001	24.84/<0.001	11.30/<0.001
对照组vs空白对照组		7.14/<0.001	3.70/<0.001	11.69/0.035	3.01/0.035

表2 治疗第5天时，3组病毒性ARI患儿临床疗效比较[例数(%)]

组别	例数	临床痊愈	显效率	有效率	无效率	总有效率
研究组	42	9(21.4)	3(56.1)	9(21.4)	1(2.4)	1(97.6)
对照组	42	8(19.0)	18(42.9)	8(19.0)	8(19.0)	34(80.9)
空白对照组	42	7(16.7)	16(39.1)	9(21.4)	9(21.4)	33(78.5)
总体比较(χ²值/P值)		－	－	－	－	7.39/0.025
两两比较(χ²值/P值)
研究组vs对照组		－	－	－	－	6.10/0.014
研究组vs空白对照组		－	－	－	－	7.26/0.007
对照组vs空白对照组		－	－	－	－	0.07/0.786

表2 治疗第5天时，3组病毒性ARI患儿临床疗效比较[例数(%)]

组别	例数	临床痊愈	显效率	有效率	无效率	总有效率
研究组	42	9(21.4)	3(56.1)	9(21.4)	1(2.4)	1(97.6)
对照组	42	8(19.0)	18(42.9)	8(19.0)	8(19.0)	34(80.9)
空白对照组	42	7(16.7)	16(39.1)	9(21.4)	9(21.4)	33(78.5)
总体比较(χ²值/P值)		－	－	－	－	7.39/0.025
两两比较(χ²值/P值)
研究组vs对照组		－	－	－	－	6.10/0.014
研究组vs空白对照组		－	－	－	－	7.26/0.007
对照组vs空白对照组		－	－	－	－	0.07/0.786

表3 治疗前与治疗第5天时，3组病毒性ARI患儿血清免疫指标比较(`±s)

组别	例数	CD4⁺(%)		CD8⁺(%)		CD4⁺/CD8⁺
组别	例数	治疗前	治疗第5天时	治疗前	治疗第5天时	治疗前	治疗第5天时
研究组	42	32.9±2.8	44.3±3.8	32.0±2.8	25.4±2.8	1.03±0.10	1.71±0.25
对照组	42	33.7±3.3	39.1±4.2	32.9±2.1	27.1±3.0	1.03±0.11	1.44±0.27
空白对照组	42	32.6±2.5	36.3±4.0	33.0±2.2	29.6±3.2	1.05±0.12	1.31±0.22
总体比较(F值/P值)		1.79/0.171	42.31/<0.001	2.25/0.110	21.30/<0.001	0.46/0.632	28.54/<0.001
两两比较(q值/P值)
研究组vs对照组		1.93/0.175	8.29/<0.001	2.35/0.991	3.78/0.009	0.001/0.999	7.07/<0.001
研究组vs空白对照组		0.65/0.646	12.83/<0.001	2.78/0.510	9.18/<0.001	1.18/0.407	10.47/<0.001
对照组vs空白对照组		2.58/0.071	4.53/<0.001	0.44/0.758	5.41/<0.001	1.18/0.407	3.40/0.017
组内治疗第5天时vs治疗前(t值/P值)
研究组		5.71/<0.001		6.39/<0.001		25.33/<0.001
对照组		6.35/<0.001		5.88/<0.001		19.68/<0.001
空白对照组		6.00/<0.001		4.99/<0.001		16.32/<0.001

表3 治疗前与治疗第5天时，3组病毒性ARI患儿血清免疫指标比较(`±s)

组别	例数	CD4⁺(%)		CD8⁺(%)		CD4⁺/CD8⁺
组别	例数	治疗前	治疗第5天时	治疗前	治疗第5天时	治疗前	治疗第5天时
研究组	42	32.9±2.8	44.3±3.8	32.0±2.8	25.4±2.8	1.03±0.10	1.71±0.25
对照组	42	33.7±3.3	39.1±4.2	32.9±2.1	27.1±3.0	1.03±0.11	1.44±0.27
空白对照组	42	32.6±2.5	36.3±4.0	33.0±2.2	29.6±3.2	1.05±0.12	1.31±0.22
总体比较(F值/P值)		1.79/0.171	42.31/<0.001	2.25/0.110	21.30/<0.001	0.46/0.632	28.54/<0.001
两两比较(q值/P值)
研究组vs对照组		1.93/0.175	8.29/<0.001	2.35/0.991	3.78/0.009	0.001/0.999	7.07/<0.001
研究组vs空白对照组		0.65/0.646	12.83/<0.001	2.78/0.510	9.18/<0.001	1.18/0.407	10.47/<0.001
对照组vs空白对照组		2.58/0.071	4.53/<0.001	0.44/0.758	5.41/<0.001	1.18/0.407	3.40/0.017
组内治疗第5天时vs治疗前(t值/P值)
研究组		5.71/<0.001		6.39/<0.001		25.33/<0.001
对照组		6.35/<0.001		5.88/<0.001		19.68/<0.001
空白对照组		6.00/<0.001		4.99/<0.001		16.32/<0.001

表4 治疗前与治疗第5天时，3组病毒性ARI患儿血清IgM、IgG与IgA水平比较(g/L ，±s)

组别	例数	IgM		IgG		IgA
组别	例数	治疗前	治疗第5天时	治疗前	治疗第5天时	治疗前	治疗第5天时
空白对照组	42	1.05±0.15	1.16±0.11	5.63±1.52	6.19±1.36	1.22±0.21	1.40±0.23
对照组	42	1.05±0.13	1.22±0.10	5.37±1.17	7.26±2.01	1.21±0.23	1.59±0.37
研究组	42	1.06±0.15	1.37±0.12	5.86±1.32	9.57±1.84	1.24±0.20	1.77±0.21
总体比较(F值/P值)		0.07/0.934	40.39/<0.001	1.40/0.251	40.54/<0.001	0.22/0.807	20.06/<0.001
两两比较(q值/P值)
研究组vs对照组		0.001/0.999	3.52/0.014	1.25/0.377	3.94/0.006	0.30/0.830	4.41/0.002
研究组vs空白对照组		0.45/0.750	12.34/<0.001	1.11/0.434	12.46/<0.001	0.61/0.669	8.59/<0.001
对照组vs空白对照组		0.45/0.750	8.81/<0.001	2.36/0.097	8.51/<0.001	0.91/0.521	4.18/0.004
组内治疗第5天时vs治疗前(t值/P值)
研究组		7.59/<0.001		6.35/<0.001		9.65/<0.001
对照组		8.32/<0.001		8.01/<0.001		10.29/<0.001
空白对照组		9.66/<0.001		8.54/<0.001		11.03/<0.001

表4 治疗前与治疗第5天时，3组病毒性ARI患儿血清IgM、IgG与IgA水平比较(g/L ，±s)

组别	例数	IgM		IgG		IgA
组别	例数	治疗前	治疗第5天时	治疗前	治疗第5天时	治疗前	治疗第5天时
空白对照组	42	1.05±0.15	1.16±0.11	5.63±1.52	6.19±1.36	1.22±0.21	1.40±0.23
对照组	42	1.05±0.13	1.22±0.10	5.37±1.17	7.26±2.01	1.21±0.23	1.59±0.37
研究组	42	1.06±0.15	1.37±0.12	5.86±1.32	9.57±1.84	1.24±0.20	1.77±0.21
总体比较(F值/P值)		0.07/0.934	40.39/<0.001	1.40/0.251	40.54/<0.001	0.22/0.807	20.06/<0.001
两两比较(q值/P值)
研究组vs对照组		0.001/0.999	3.52/0.014	1.25/0.377	3.94/0.006	0.30/0.830	4.41/0.002
研究组vs空白对照组		0.45/0.750	12.34/<0.001	1.11/0.434	12.46/<0.001	0.61/0.669	8.59/<0.001
对照组vs空白对照组		0.45/0.750	8.81/<0.001	2.36/0.097	8.51/<0.001	0.91/0.521	4.18/0.004
组内治疗第5天时vs治疗前(t值/P值)
研究组		7.59/<0.001		6.35/<0.001		9.65/<0.001
对照组		8.32/<0.001		8.01/<0.001		10.29/<0.001
空白对照组		9.66/<0.001		8.54/<0.001		11.03/<0.001

表5 治疗第5天时，3组病毒性ARI患儿治疗相关不良反应总发生率比较[例数(%)]

组别	例数	腹泻	恶心	总发生率
研究组	42	3(7.1)	2(4.8)	5(11.9)
对照组	42	2(4.8)	1(2.4)	3(7.1)
空白对照组	42	2(4.8)	0(0)	2(4.8)
总体比较(P值)		－	－	0.468

表5 治疗第5天时，3组病毒性ARI患儿治疗相关不良反应总发生率比较[例数(%)]

组别	例数	腹泻	恶心	总发生率
研究组	42	3(7.1)	2(4.8)	5(11.9)
对照组	42	2(4.8)	1(2.4)	3(7.1)
空白对照组	42	2(4.8)	0(0)	2(4.8)
总体比较(P值)		－	－	0.468

[1]	Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of respiratory viral infections[J]. Annu Rev Virol, 2020, 7(1): 83-101. DOI：10.1146/annurev-virology-012420-022445.
[2]	夏金蓉，王慧，刘玉珊，等. COVID-19疫情暴发前、后呼吸道感染住院患儿呼吸道病原体的变化[J/OL]. 中华妇幼临床医学杂志(电子版), 2022, 18(6): 712-721. DOI: 10.3877/cma.j.issn.1673-5250.2022.06.013.
[3]	李斌，孙勇生，李海英. 连花清瘟颗粒对病毒性上呼吸道感染发热患儿的疗效及对血清淀粉样蛋白A、炎症因子表达的影响[J]. 中药材，2020, 43(6): 1486-1489. DOI: 10.13863/j.issn1001-4454.2020.06.039.
[4]	王天有，申昆玲，沈颖，等．诸福棠实用儿科学(9版)[M]. 北京：人民卫生出版社，2022: 1363.
[5]	郑筱萸. 中药新药临床研究指南原则：试行[M]. 北京：中国医药科技出版社，2002: 57-58.
[6]	Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med, 2020, 46(2): 298-314. DOI：10.1007/s00134-019-05906-5.
[7]	黄羚，刘铁钢，白辰，等. 基于数据挖掘和网络药理学的谷晓红教授治疗小儿急性上呼吸道感染的研究[J]. 世界中医药，2020, 15(20): 3007-3013. DOI：10.3969/j.issn.1673-7202.2020.20.001.
[8]	连晓峰，韩鹏，李永锋，等. 细胞免疫应答变化与支气管哮喘疾病进展的相关性分析[J]. 广东医学，2021, 42(3): 279-282. DOI: 10.13820/j.cnki.gdyx.20192320.
[9]	刘萍萍，谢宝强，业晓青，等. 反复呼吸道感染儿童细胞免疫与体液免疫研究[J]. 中国预防医学杂志，2019, 8(2): 3-6. DOI: 10.16506/j.1009-6639.2019.02.012.
[10]	李丽嫱，王竹颖，徐娟玉，等. 支原体肺炎患儿血清IgM、IgG、IgA、T细胞亚群及炎症因子水平观察[J]. 传染病信息，2019, 32(3): 239-241. DOI: 10.3969/j.issn.1007-8134.2019.03.011.
[11]	黄娜，成晓君，刘颖，等. 儿童维生素A缺乏与反复呼吸道感染相关性研究[J]. 中国儿童保健杂志，2020, 28(8): 925-927, 952. DOI：10.11852/zgetbjzz2019-1321.
[12]	陈冉，王婷婷，李开铃，等. 免疫调节抗病毒中药的特性与应用[J]. 中草药，2020, 51(6): 1412-1426. DOI: 10.7501/j.issn.0253-2670.2020.06.006.

[1]	Hongyu Tao, Jingjing Ye, Jin Yu, Xiuzhen Yang, Jingjing Qian, Bin Xu, Weize Xu, Qiang Shu. Value of contrast transthoracic echocardiography in assessing right-to-left shunt-related diseases in children[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(10): 959-965.
[2]	Xiaofei Li, Hongli Liu, Qiuling Shi, Jing Tian, Li Li, Hongbo Qi, Xin Luo. A prospective randomized controlled study of low intensity focused ultrasound uterine involution treatment for prevention and treatment of postpartum hemorrhage in natural childbirth women[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 534-539.
[3]	Qin Liu, Hanmin Liu, Liang Xie. Current status of research on the role of matrix metalloproteinases in the pathogenesis of childhood asthma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 564-568.
[4]	Yun Xiang, You Lu, Fan Yang. Current research status of correlation between per-and polyfluoroalkyl substances exposure and childhood obesity[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 569-574.
[5]	Mengsi Zhang, Yiqun Ma, Lijuan Meng, Hui Zhu, Jinfeng Fu. Observation on the effect of the combined use of pressure gloves, webbed finger compression straps and foam silicone gel sheeting after surgery in children with cicatricial syndactyly[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(04): 329-334.
[6]	Xiaoli Yang, Wanfu Li, Zhu Ma, Lan Ma, Yi Zheng, Xiaoli Fu, Jing Wang. Application effect of one-step forceps needle method in laparoscopic high ligation of hernia sac in children[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 535-538.
[7]	Hebei Ding, Xun Wang, Weiguo Chen. Comparison of application of sevoflurane inhalation anesthesia and propofol intravenous anesthesia in pediatric indirect inguinal hernia surgery[J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(05): 570-574.
[8]	Jixiao Zeng, Xiaogang Xu, Xinxing Wang, Fei Liu, Menglong Lan, Boyuan Tao, Zijian Liang, Zhihua Ye, Yuanyuan Luo. Da Vinci robotic-assisted Swenson-like pull through for Hirschsprung disease[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(04): 239-243.
[9]	Chinese Society of Organ Transplantation of Chinese Medical Association, Surgery Group of Chinese Society of Surgery of Chinese Medical Association, Transplantation Group of Chinese Society of Surgery of Chinese Medical Association, South China Alliance of Split Liver Transplantation. Chinese Clinical Practice Guidelines on Split Liver Transplantation in Children[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 593-601.
[10]	Jun Liu, Wenjing Qiu, Fanghao Sun, Songying Li, Shuhong Yi, Binsheng Fu, Yang Yang, Hui Luo. Comparison of in vivo and in vitro split liver transplantation in pediatric liver transplantation[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 688-693.
[11]	Chen Zhang, Ming Qin, Juan Dong, Yulong Chen. Diagnostic value of ultrasound in ischemic changes of intestinal volvulus in children[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 565-568.
[12]	Xiaoyu Wang, Qunying Guo, Yameng Niu, Chengsong Zhao. Practice of promoting equal access to pediatric medical care in public children's hospitals[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(04): 383-387.
[13]	Wenjuan Li, Fan Yang, Anqi Zhang, Xiaoqing Yin, Yuanyuan Li, Fangfan Zheng. Correlation between the imaging manifestation of spina bifida occulta and clinical symptoms and curative effect in children with nocturnal enuresis[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(04): 356-361.
[14]	Xiaosheng Chen, Jia He, Fang Liu, Rui Wu, Haitao Yang, Xiaohan Fan. Pacemaker implantation in a child with a 31-second cardiac arrest induced by tilt table test: a case report and literature review[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(05): 488-494.
[15]	Yali Cao, Yumeng Gao, Yingqian Zhang, Bo Li, Junbao Du, Hongfang Jin. Clinical progress of sitting intolerance in children[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(05): 510-515.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export